JP2014509838A5 - - Google Patents

Download PDF

Info

Publication number
JP2014509838A5
JP2014509838A5 JP2013547811A JP2013547811A JP2014509838A5 JP 2014509838 A5 JP2014509838 A5 JP 2014509838A5 JP 2013547811 A JP2013547811 A JP 2013547811A JP 2013547811 A JP2013547811 A JP 2013547811A JP 2014509838 A5 JP2014509838 A5 JP 2014509838A5
Authority
JP
Japan
Prior art keywords
peptide
seq
sequence
monomeric
isolated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013547811A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014509838A (ja
JP6294076B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/DK2012/050010 external-priority patent/WO2012092934A1/en
Publication of JP2014509838A publication Critical patent/JP2014509838A/ja
Publication of JP2014509838A5 publication Critical patent/JP2014509838A5/ja
Application granted granted Critical
Publication of JP6294076B2 publication Critical patent/JP6294076B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013547811A 2011-01-06 2012-01-06 多量体ペプチド Expired - Fee Related JP6294076B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP11150323.1 2011-01-06
EP11150323 2011-01-06
US201161475988P 2011-04-15 2011-04-15
US61/475,988 2011-04-15
PCT/DK2012/050010 WO2012092934A1 (en) 2011-01-06 2012-01-06 Monomeric and multimeric immunogenic peptides

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016216620A Division JP2017048232A (ja) 2011-01-06 2016-11-04 多量体ペプチド

Publications (3)

Publication Number Publication Date
JP2014509838A JP2014509838A (ja) 2014-04-24
JP2014509838A5 true JP2014509838A5 (enExample) 2015-02-12
JP6294076B2 JP6294076B2 (ja) 2018-03-14

Family

ID=43971370

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2013547811A Expired - Fee Related JP6294076B2 (ja) 2011-01-06 2012-01-06 多量体ペプチド
JP2016216620A Pending JP2017048232A (ja) 2011-01-06 2016-11-04 多量体ペプチド

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016216620A Pending JP2017048232A (ja) 2011-01-06 2016-11-04 多量体ペプチド

Country Status (11)

Country Link
US (2) US9493514B2 (enExample)
EP (2) EP3338798A1 (enExample)
JP (2) JP6294076B2 (enExample)
KR (1) KR101993431B1 (enExample)
CN (1) CN103347892B (enExample)
AU (1) AU2012204955B2 (enExample)
BR (1) BR112013017488A2 (enExample)
CA (1) CA2821995C (enExample)
EA (1) EA034031B1 (enExample)
MX (1) MX346475B (enExample)
WO (1) WO2012092934A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2014014683A (es) 2012-06-06 2015-02-24 Bionor Immuno As Peptidos derivados de proteinas virales para usarse como inmunogenos y reactivos de dosificacion.
CA2875624A1 (en) 2012-06-06 2013-12-12 Bionor Immuno As Hiv vaccine
CA2889064A1 (en) 2012-10-19 2014-04-24 The Council Of The Queensland Institute Of Medical Research Improved human herpesvirus immunotherapy
WO2014159931A1 (en) * 2013-03-13 2014-10-02 Washington State University Strings of epitopes useful in diagnosing and eliciting immune responses to sexually trasmitted infections
WO2015007337A1 (en) 2013-07-19 2015-01-22 Bionor Immuno As Method for the vaccination against hiv
AU2015208033B2 (en) 2014-01-27 2019-02-07 Bionor Immuno As Method for the vaccination against HIV
WO2016042131A1 (en) * 2014-09-18 2016-03-24 The Provost, Fellows, Foundation Scholars, & The Other Members Of Board, Of The College Of The Holy & Undiv. Trinity Of Queen Elizabeth Near Dublin Use of inhibitors of il-36 proteolytic processing for the treatment and/or reduction of inflammation
EP4276106A3 (en) * 2015-05-13 2024-01-24 The United States of America as represented by the Secretary of the Department of Health and Human Services Methods and compositions for inducing an immune response using conserved element constructs
KR101859223B1 (ko) * 2016-11-29 2018-06-01 단디바이오사이언스 주식회사 고병원성 인플루엔자 바이러스 검출용 마커 및 이의 용도
WO2018141089A1 (zh) * 2017-02-04 2018-08-09 中国医学科学院病原生物学研究所 广谱抑制hiv的脂肽、其衍生物、其药物组合物及其用途
US10677798B2 (en) 2017-11-22 2020-06-09 Washington State University Strings of epitopes useful in diagnosing and eliciting immune responses to sexually transmitted infections
GB201903132D0 (en) * 2019-03-08 2019-04-24 Queens Univ Of Belfast A peptide for the delivery of anionic materials
CN111221983B (zh) 2020-01-15 2023-08-04 北京百度网讯科技有限公司 时序知识图谱生成方法、装置、设备和介质
CN116832720B (zh) * 2023-06-19 2025-11-21 广州聚焦生物科技有限公司 一种发光免疫检测的冻干微球及其制备方法
CN118684745B (zh) * 2024-06-07 2025-12-09 中国医学科学院病原生物学研究所 一种抗hiv-1多肽及其衍生物和应用

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
US4609546A (en) 1982-06-24 1986-09-02 Japan Chemical Research Co., Ltd. Long-acting composition
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4606918A (en) 1983-08-22 1986-08-19 Syntex (U.S.A.) Inc. Polyoxypropylene-polyoxyethylene block polymer based adjuvants
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
CA1294215C (en) 1986-10-27 1992-01-14 Ze'ev Shaked Pharmaceutical compositions of recombinant beta-interferon and formulation processes
CA1292686C (en) 1986-10-27 1991-12-03 Ze'ev Shaked Pharmaceutical compositions of recombinant interleukin-2 and formulation process
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
ATE128716T1 (de) * 1987-11-24 1995-10-15 Abbott Lab Hiv-peptide und methoden für den nachweis von hiv.
EP0328390B1 (en) * 1988-02-10 1994-09-14 Immulogic Pharmaceutical Corporation Peptide treatment of refractory infectious diseases
CA1341285C (en) * 1988-02-12 2001-08-14 Chang Yi Wang Synthetic peptides for the detection of antibodies to hiv gp120 envelope protein for diagnosis of aids and pre-aids conditions and as vaccines
MA22842A1 (fr) 1992-03-27 1993-10-01 Smithkline Beecham Biolog Procede de preparation de compositions de vaccin.
DE69319728T2 (de) 1992-05-23 1999-02-04 Smithkline Beecham Biologicals S.A., Rixensart Kombinierte Impfstoffe, die Hepatitis B oberfläche Antigen und andere Antigenen enthalten
CA2138997C (en) 1992-06-25 2003-06-03 Jean-Paul Prieels Vaccine composition containing adjuvants
SG48309A1 (en) 1993-03-23 1998-04-17 Smithkline Beecham Biolog Vaccine compositions containing 3-0 deacylated monophosphoryl lipid a
JP3926839B2 (ja) 1993-09-14 2007-06-06 エピミューン,インコーポレイティド 万能dr−結合性ペプチドを用いる免疫応答の改変
PT992580E (pt) 1993-11-04 2005-07-29 Innogenetics Nv Epitopos para celulas t humanas imunodominantes do virus da hepatite c
JP3002702B2 (ja) 1993-11-16 2000-01-24 スカイファーム インコーポレーテッド 活性物質の制御放出を有する小胞
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US5709995A (en) 1994-03-17 1998-01-20 The Scripps Research Institute Hepatitis C virus-derived peptides capable of inducing cytotoxic T lymphocyte responses
JPH10503473A (ja) 1994-04-08 1998-03-31 アメリカ合衆国 細胞傷害性tリンパ球刺激およびhcv曝露診断用c型肝炎ウイルスコアペプチド
GB9513261D0 (en) 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines
JPH0950531A (ja) 1995-08-09 1997-02-18 Fuji Xerox Co Ltd 画像処理装置
DE69733352T2 (de) 1996-03-21 2006-04-27 Epimmune, Inc., San Diego Hla-a2.1 bindende peptide und deren verwendung
JP3945822B2 (ja) 1996-05-24 2007-07-18 カイロン コーポレイション 複数エピトープ融合タンパク質
US6566330B1 (en) 1996-10-22 2003-05-20 Medical University Of South Carolina Foundation Research Development Positively charged non-natural amino acids, methods of making and using thereof in peptides
CN1195702A (zh) * 1997-04-08 1998-10-14 军事医学科学院基础医学研究所 Hiv-1多表位重组膜抗原及其表达
GB9711990D0 (en) 1997-06-11 1997-08-06 Smithkline Beecham Biolog Vaccine
GB9712347D0 (en) 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
CA2345817C (en) 1998-10-05 2013-02-12 M&E Biotech A/S Novel methods for therapeutic vaccination
HK1044040A1 (zh) * 1998-11-16 2002-10-04 德克萨斯州立大学董事会 Hiv-特异的t-细胞诱导
WO2001021189A1 (en) 1999-07-19 2001-03-29 Epimmune Inc. Inducing cellular immune responses to hepatitis c virus using peptide and nucleic acid compositions
EP1125905A1 (en) 2000-02-16 2001-08-22 Pepscan Systems B.V. Segment synthesis
GB0005703D0 (en) 2000-03-09 2000-05-03 Alpharma As Compounds
WO2002020035A1 (en) 2000-09-01 2002-03-14 Epimmune Inc. Hla binding peptides and their uses
NO314588B1 (no) * 2000-09-04 2003-04-14 Bionor Immuno As HIV-peptider, antigener, vaksinesammensetning, immunoassay- testsett og en fremgangsmåte for å påvise antistoffer indusert av HIV
EP1195381A1 (de) 2000-09-28 2002-04-10 Immusystems GmbH CD4+ T-Lymphozyten spezifische Hepatitis C Virus-Epitope
GB0026094D0 (en) 2000-10-25 2000-12-13 Imp College Innovations Ltd Methods
AU2003236728A1 (en) 2002-06-10 2003-12-22 Algonomics N.V. Method for predicting the binding affinity of mhc/peptide complexes
WO2004024182A2 (en) 2002-09-13 2004-03-25 Intercell Ag Method for isolating hepatitis c virus peptides
KR101399678B1 (ko) * 2003-01-15 2014-05-27 추가이 세이야쿠 가부시키가이샤 이량체화 펩티드
MXPA06014065A (es) 2004-06-01 2007-01-31 Genentech Inc Conjugados de droga-anticuerpo y metodos.
EP1652858A1 (en) 2004-10-28 2006-05-03 Innogenetics N.V. Peptides for inducing a CTL and/or HTL response to hepatitis C virus
AU2005316844A1 (en) 2004-11-29 2006-06-22 Seattle Genetics, Inc. Engineered antibodies and immunoconjugates
WO2010056796A1 (en) * 2008-11-12 2010-05-20 Theraclone Sciences, Inc. Human m2e peptide immunogens
US9066983B2 (en) * 2009-05-18 2015-06-30 National University Corporation Tokyo Medical And Dental University Peptidic antigen that induces antibody recognizing three-dimensional structure of HIV and method for synthesizing same
JP5946766B2 (ja) * 2009-07-03 2016-07-06 ビオノール イミュノ エーエスBionor Immuno As Hivワクチン組成物における使用又は診断手段としての使用のためのhiv関連ペプチドの組合せ又は融合物
CN103282375B (zh) 2010-12-02 2017-01-11 比奥诺尔免疫有限公司 肽支架设计

Similar Documents

Publication Publication Date Title
CY1123762T1 (el) Καινοτομος ανοσοθεραπεια εναντι διαφορων ογκων συμπεριλαμβανομενου του γαστρεντερικου και του γαστρiκου καρκινου
JP2015528443A5 (enExample)
JP2014502156A5 (enExample)
JP2012510431A5 (enExample)
JP2015529678A5 (enExample)
HRP20150873T1 (hr) Pripravci i postupci za lijeäśenje celijakije
JP2012531219A5 (enExample)
KR101736897B1 (ko) 인플루엔자 항원 수송 벡터 및 구조물
JP2012511322A5 (enExample)
IL276170B2 (en) Lipid-modified relaxin B peptide chains and their medical use
JP2014507146A5 (enExample)
JP2010539901A5 (enExample)
JP2008530975A5 (enExample)
JP2017501990A5 (enExample)
JP2014502961A5 (enExample)
JP2016520534A5 (enExample)
JP2009500298A5 (enExample)
RU2015140603A (ru) Вакцины на основе нуклеопротеина вируса гриппа
JP2019526261A5 (enExample)
JP2013517764A5 (enExample)
WO2013054329A1 (en) Toll-like receptor 4 (tlr-4) agonist peptides for modulating tlr-4 mediated immune response
JP2018536645A5 (enExample)
JP2019534242A5 (enExample)
JP2015524652A5 (enExample)
JP2012526519A5 (enExample)